Raymond James Financial Inc. acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 4,855 shares of the company's stock, valued at approximately $225,000.
A number of other large investors have also recently added to or reduced their stakes in VRNA. GAMMA Investing LLC raised its holdings in shares of Verona Pharma by 20.7% in the 4th quarter. GAMMA Investing LLC now owns 1,612 shares of the company's stock valued at $75,000 after purchasing an additional 276 shares during the period. EMC Capital Management boosted its stake in shares of Verona Pharma by 3,400.0% during the 4th quarter. EMC Capital Management now owns 3,500 shares of the company's stock worth $163,000 after acquiring an additional 3,400 shares during the period. Wrapmanager Inc. acquired a new position in shares of Verona Pharma during the 4th quarter worth approximately $207,000. Sanctuary Advisors LLC bought a new stake in Verona Pharma in the 3rd quarter valued at $219,000. Finally, Transcend Capital Advisors LLC bought a new position in Verona Pharma during the fourth quarter worth $225,000. Institutional investors own 85.88% of the company's stock.
Insider Activity at Verona Pharma
In related news, insider Kathleen A. Rickard sold 79,264 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $8.35, for a total value of $661,854.40. Following the completion of the transaction, the insider now directly owns 2,608,976 shares of the company's stock, valued at $21,784,949.60. This represents a 2.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.80% of the stock is currently owned by company insiders.
Verona Pharma Price Performance
Shares of NASDAQ:VRNA traded up $0.66 on Tuesday, hitting $58.47. The company's stock had a trading volume of 478,155 shares, compared to its average volume of 1,205,598. Verona Pharma plc has a 1 year low of $11.39 and a 1 year high of $70.40. The company has a debt-to-equity ratio of 0.93, a current ratio of 13.03 and a quick ratio of 12.88. The company has a market capitalization of $4.73 billion, a PE ratio of -30.45 and a beta of 0.16. The company has a 50-day simple moving average of $62.53 and a 200 day simple moving average of $48.90.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on VRNA shares. Roth Capital set a $83.00 target price on Verona Pharma in a report on Friday, February 28th. Truist Financial restated a "buy" rating and set a $57.00 target price (up previously from $44.00) on shares of Verona Pharma in a research report on Wednesday, January 8th. Wells Fargo & Company increased their price target on Verona Pharma from $74.00 to $93.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Canaccord Genuity Group boosted their price target on Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Finally, Roth Mkm assumed coverage on Verona Pharma in a report on Friday, January 10th. They issued a "buy" rating and a $68.00 target price on the stock. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $69.14.
Read Our Latest Report on VRNA
Verona Pharma Profile
(
Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
See Also
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
